» Articles » PMID: 33888065

Olaparib-mediated Enhancement of 5-fluorouracil Cytotoxicity in Mismatch Repair Deficient Colorectal Cancer Cells

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2021 Apr 23
PMID 33888065
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The advances in colorectal cancer (CRC) treatment include the identification of deficiencies in Mismatch Repair (MMR) pathway to predict the benefit of adjuvant 5-fluorouracil (5-FU) and oxaliplatin for stage II CRC and immunotherapy. Defective MMR contributes to chemoresistance in CRC. A growing body of evidence supports the role of Poly-(ADP-ribose) polymerase (PARP) inhibitors, such as Olaparib, in the treatment of different subsets of cancer beyond the tumors with homologous recombination deficiencies. In this work we evaluated the effect of Olaparib on 5-FU cytotoxicity in MMR-deficient and proficient CRC cells and the mechanisms involved.

Methods: Human colon cancer cell lines, proficient (HT29) and deficient (HCT116) in MMR, were treated with 5-FU and Olaparib. Cytotoxicity was assessed by MTT and clonogenic assays, apoptosis induction and cell cycle progression by flow cytometry, DNA damage by comet assay. Adhesion and transwell migration assays were also performed.

Results: Our results showed enhancement of the 5-FU citotoxicity by Olaparib in MMR-deficient HCT116 colon cancer cells. Moreover, the combined treatment with Olaparib and 5-FU induced G2/M arrest, apoptosis and polyploidy in these cells. In MMR proficient HT29 cells, the Olaparib alone reduced clonogenic survival, induced DNA damage accumulation and decreased the adhesion and migration capacities.

Conclusion: Our results suggest benefits of Olaparib inclusion in CRC treatment, as combination with 5-FU for MMR deficient CRC and as monotherapy for MMR proficient CRC. Thus, combined therapy with Olaparib could be a strategy to overcome 5-FU chemotherapeutic resistance in MMR-deficient CRC.

Citing Articles

PARP Inhibitors in Colorectal Malignancies: A 2023 Update.

Skouteris N, Papageorgiou G Rev Recent Clin Trials. 2023; 19(2):101-108.

PMID: 38058097 DOI: 10.2174/0115748871260815231116060817.


Research progress of traditional Chinese medicine as sensitizer in reversing chemoresistance of colorectal cancer.

Lin X, Yang X, Yang Y, Zhang H, Huang X Front Oncol. 2023; 13:1132141.

PMID: 36994201 PMC: 10040588. DOI: 10.3389/fonc.2023.1132141.


Identification of an m6A-Related Long Noncoding RNA Risk Model for Predicting Prognosis and Directing Treatments in Patients With Colon Adenocarcinoma.

Liao W, Long J, Li Y, Xie F, Xun Z, Wang Y Front Cell Dev Biol. 2022; 10:910749.

PMID: 35912098 PMC: 9326028. DOI: 10.3389/fcell.2022.910749.


Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer.

Papageorgiou G, Fergadis E, Skouteris N, Christakos E, Tsakatikas S, Lianos E Front Oncol. 2022; 11:788809.

PMID: 35004311 PMC: 8728007. DOI: 10.3389/fonc.2021.788809.


Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models.

Dahlmann M, Gambara G, Brzezicha B, Popp O, Pachmayr E, Wedeken L Mol Cancer. 2021; 20(1):129.

PMID: 34670579 PMC: 8529724. DOI: 10.1186/s12943-021-01430-7.


References
1.
Maya-Mendoza A, Moudry P, Merchut-Maya J, Lee M, Strauss R, Bartek J . High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018; 559(7713):279-284. DOI: 10.1038/s41586-018-0261-5. View

2.
Park J, Huang S, Tougeron D, Sinicrope F . MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. PLoS One. 2013; 8(5):e65369. PMC: 3665625. DOI: 10.1371/journal.pone.0065369. View

3.
Hammond W, Swaika A, Mody K . Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016; 8(1):57-84. PMC: 4699262. DOI: 10.1177/1758834015614530. View

4.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G . Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366(15):1382-92. DOI: 10.1056/NEJMoa1105535. View

5.
Fearon E . Molecular genetics of colorectal cancer. Annu Rev Pathol. 2010; 6:479-507. DOI: 10.1146/annurev-pathol-011110-130235. View